Chronic liver disease poses significant challenges to healthcare systems, which frequently struggle to meet the needs of end-stage liver disease patients. Early detection and management are essential because liver damage and fibrosis are potentially reversible. However, the implementation of population-wide screenings is hindered by the asymptomatic nature of early chronic liver disease, along with the risks and costs associated with traditional diagnostics, such as liver biopsies. This study pioneers the development of innovative, minimally invasive methods capable of improving the outcomes of liver disease patients by identifying liver disease biomarkers using quantification methods with translational potential. A targeted mass spectrometry assay based on stable isotope standard protein epitope signature tags (SIS-PrESTs) was employed for the absolute quantification of 108 proteins in just two microliters of plasma. The plasma profiles were derived from patients of various liver disease stages and etiologies, including healthy controls. A set of potential biomarkers for stratifying liver fibrosis was identified through differential expression analysis and supervised machine learning. These findings offer promising alternatives for improved diagnostics and personalized treatment strategies in liver disease management. Moreover, our approach is fully compatible with existing technologies that facilitate the robust quantification of clinically relevant protein targets via minimally disruptive sampling methods.
Targeted proteomics offers high precision, reproducibility, and multiplexing capabilities for quantifying proteins in complex biological samples, making the technology into a powerful tool for biomarker discovery and clinical diagnostics. When combined with at-home microsampling, this approach has the potential to transform population-level screening and longitudinal studies and can pave the way for decentralized healthcare. One of the main advantages of this combined approach is that samples can be collected offsite and then transported and stored as dried blood spots (DBSs). Currently, innovative volumetric microfluidic devices have also enabled DBS microsampling of consistently precise volumes. However, the reliability of the molecular data obtained with this mode of sampling still needs to be investigated and validated. In this study, 72 deidentified blood samples from two individuals were collected using DBS microsampling device CapitainerB and analyzed using targeted mass spectrometry and quantitative recombinant protein standards (qRePSs). The DBSs were subjected to three simulated and realistic shipping environmental conditions and stored in two different types of containers to assess sample stability. The results suggest that shipping conditions and storage at high temperatures often observed during summer have an impact on protein identification and quantification results, highlighting the need for further research to ensure biomarker reliability for dispersed microsampling.